Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

FRP Advisory trading in line with market expectations

(Sharecast News) - Business advisory firm FRP Advisory Group reported significant progress in the first nine months of the financial year in a trading update on Wednesday. The AIM-traded company said current levels of trading activity aligned with market expectations for revenue of £123m, and adjusted EBITDA of £32m.

It said it was planning to release a comprehensive trading update for the entire 2024 financial year in mid-May.

In terms of the quarterly dividend, the group said it had a robust balance sheet and a net cash position.

Under its established dividend policy, the board announced a dividend for the third quarter ended 31 January of 0.9p per eligible share.

The dividend was scheduled to be paid on 14 June to shareholders on record as of 17 May, with the ex-dividend date being set for 16 May.

At 1034 GMT, shares in FRP Advisory Group were down 0.83% at 126.44p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Yellow Cake NAV slips as uranium values decline
(Sharecast News) - Uranium investor Yellow Cake reported a rise in uranium holdings but a decrease in net asset value due to lower spot prices in its interim results on Tuesday.
Digitalbox FY EBITDA now seen ahead of internal expectations
(Sharecast News) - Digital media business Digtalbox said on Tuesday that it now expects FY24 revenues to be at least £3.5m, while underlying earnings were also seen ahead of management's expectations.
Dianomi expects to record small loss in FY24
(Sharecast News) - Digital advertising business Dianomi warned on Tuesday that it and to record a small loss in FY24 compared to market expectations of a small profit.
Ixico secures new contract with US-based client
(Sharecast News) - Neuroscience imaging firm Ixico has signed a contract with a new US-based client to provide imaging services for a Phase 2 Huntington's Disease clinical trial.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.